Tau Pathology Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
The tau pathology pathway is central to Alzheimer's disease (AD) pathogenesis and represents one of the two hallmark proteinopathies in AD, alongside amyloid-beta plaques. Tau is a microtubule-associated protein that stabilizes neuronal axons under normal conditions. In AD and related tauopathies, tau undergoes pathological transformation including hyperphosphorylation, misfolding, oligomerization, and aggregation into neurofibrillary tangles (NFTs). The spread of tau pathology through connected brain regions correlates strongly with cognitive decline, making tau an attractive therapeutic target 1.
In the healthy brain, tau protein serves essential neuronal functions:
- Microtubule stabilization: Tau binds to microtubules via its repeat domains, promoting assembly and preventing disassembly
- Axonal transport: Tau organizes microtubule networks for efficient kinesin/dynein-mediated transport
- Synaptic modulation: Tau localizes to synapses and modulates postsynaptic signaling
- Neuronal development: Tau helps establish axonal polarity during development
The human MAPT gene produces six major tau isoforms through alternative splicing:
| Isoform |
Amino Acids |
N-terminal Inserts |
Microtubule Repeats |
| 2N4R |
441 |
Both (N1, N2) |
4 (R1-R4) |
| 2N3R |
410 |
Both |
3 (R1, R3, R4) |
| 1N4R |
432 |
N1 only |
4 |
| 1N3R |
401 |
N1 only |
3 |
| 0N4R |
383 |
None |
4 |
| 0N3R |
352 |
None |
3 |
The ratio of 3-repeat (3R) to 4-repeat (4R) tau is approximately 1:1 in the normal adult brain. This balance is disrupted in various tauopathies 2.
Tau phosphorylation is regulated by a balance of kinases and phosphatases. In AD, kinase activity predominates, leading to hyperphosphorylation.
flowchart TD
A[Normal Tau] --> B[Kinase Activation]
B --> C[GSK-3β]
B --> D[CDK5]
B --> E[MAPK Family]
B --> F[PKA]
B --> G[Src Family Kinases]
C --> H[Phosphorylation at Ser199<br/>Ser202 Thr205]
D --> H
E --> I[Phosphorylation at Ser396<br/>Ser404]
F --> I
G --> J[Phosphorylation at Tyr18]
H --> K[Hyperphosphorylated Tau]
I --> K
J --> K
K --> L[Reduced Microtubule Binding]
K --> M[Increased Aggregation]
L --> N[Axonal Transport Deficit]
M --> O[Soluble Oligomers]
O --> P[Insoluble Filaments]
P --> Q[Neurofibrillary Tangles]
Glycogen Synthase Kinase-3β (GSK-3β)
- Primary kinase responsible for tau hyperphosphorylation in AD
- Phosphorylates tau at multiple sites: Ser199, Ser202, Thr205, Ser396, Ser404
- Activity is increased by amyloid-beta and neuroinflammation
- Constitutively active in neurons, regulated by insulin signaling
Cyclin-Dependent Kinase 5 (CDK5)
- Neuron-specific kinase activated by p35/p39 regulatory subunits
- Phosphorylates similar sites as GSK-3β
- Dysregulated in AD due to calpain-mediated p35 cleavage to p25
- Prolonged activation leads to tau pathology
Mitogen-Activated Protein Kinases (MAPKs)
- ERK1/2, JNK, and p38 kinases phosphorylate tau
- Activated by cellular stress and inflammation
- Contribute to pathological phosphorylation
Protein Kinase A (PKA)
- Phosphorylates tau at Ser396 and Ser404
- Activity linked to cAMP signaling and neurotransmitter systems
The main phosphatase regulating tau phosphorylation is protein phosphatase 2A (PP2A):
- Accounts for ~70% of tau dephosphorylation activity
- PP2A activity is reduced in AD brain
- Methylation and phosphorylation of PP2A regulate its function
Hyperphosphorylated tau loses its ability to bind microtubules and gains aggregation propensity:
- Conformational change: Hyperphosphorylation exposes microtubule-binding repeats
- Nucleation: Tau dimers form via the hexapeptide motifs (PHF6* and PHF6)
- Oligomerization: Small soluble oligomers (2-12 mer) form
- Filament elongation: Oligomers seed formation of paired helical filaments (PHFs)
- NFT formation: Filaments accumulate as intracellular NFTs
flowchart LR
A[Hyperphosphorylated<br/>Tau Monomers] --> B[Conformational<br/>Change]
B --> C[ dimer formation<br/>PHF6 motifs]
C --> D[Soluble<br/>Oligomers]
D --> E[Paired Helical<br/>Filaments PHFs]
E --> F[Straight<br/>Filaments SFs]
F --> G[Neurofibrillary<br/>Tangles NFTs]
style D fill:#ffcccc
style E fill:#ff9999
style G fill:#ff6666
Paired Helical Filaments (PHFs)
- Classic filament type in AD
- C-shaped structure with ~80 nm periodicity
- Composed of full-length tau (2N4R isoform)
Straight Filaments (SFs)
- Less common than PHFs
- Often co-exist with PHFs
- Similar core structure
Growing evidence suggests different tau species have varying toxicity:
- Soluble oligomers: Most toxic, can spread between cells
- NFTs: May be less toxic as they sequester toxic oligomers
- Hyperphosphorylated tau: Dysfunctional but not yet aggregated
Tau pathology spreads through connected brain regions in a stereotypical pattern:
flowchart TD
A[Tau Pathology<br/>in Neuron] --> B[Release into<br/>Extracellular Space]
B --> C[Uptake by<br/>Connected Neuron]
C --> D[Seed Templated<br/>Aggregation]
D --> E[Local Tau<br/>Pathology]
E --> A
F[Braak Stage I-II] --> G[Entorhinal Cortex]
G --> H[Braak Stage III-IV]
H --> I[Hippocampus<br/>Amygdala]
I --> J[Braak Stage V-VI]
J --> K[Isocortex]
| Stage |
Region |
Clinical Correlation |
| I-II |
Transentorhinal cortex |
Preclinical |
| III-IV |
Limbic system (hippocampus, amygdala) |
Mild cognitive impairment |
| V-VI |
Neocortex |
Moderate to severe dementia |
- Synaptic transmission: Tau released at synapses taken up by connected neurons
- Extracellular vesicles: Tau packaged in exosomes
- Direct cell-to-cell contact: Membrane-associated tau transfer
- Fluid-phase endocytosis: Non-specific uptake of extracellular tau
Pathogenic MAPT mutations cause frontotemporal dementia with parkinsonism (FTDP-17):
| Mutation |
Type |
Effect on Tau |
| P301L |
Missense |
Reduced microtubule binding, increased aggregation |
| P301S |
Missense |
Similar to P301L |
| V337M |
Missense |
Impaired microtubule assembly |
| R406W |
Missense |
Reduced phosphorylation, altered binding |
| N279K |
Splicing |
Increases 4R tau |
| 10+16 intronic |
Splicing |
Exon 10 inclusion, 4R tau |
- H1 haplotype: Associated with PSP, CBD, PD risk
- A152T: Risk factor for AD, FTD, PSP
While amyloid and tau pathology can occur independently, there is significant crosstalk:
- Amyloid-beta exposure increases GSK-3β activity → more tau phosphorylation
- Amyloid plaques trigger neuroinflammation → kinase activation
- Tau pathology mediates amyloid-induced synaptic loss
- Combined pathology produces more severe cognitive decline
Microglial activation contributes to tau pathology:
- Inflammatory cytokines (IL-1β, TNF-α) activate kinases
- Complement proteins promote tau aggregation
- Microglia can spread tau pathology
Active Vaccination
- AADvac1: Phase 2 trials showed antibody generation
- Aim: Generate antibodies against pathological tau
Passive Immunotherapy
- Gosuranemab: Anti-tau antibody targeting N-terminal tau
- Semorinemab: Targeting mid-domain tau
- Results: Mixed efficacy in clinical trials
Aggregation Inhibitors
- Methylene blue derivatives
- Natural compounds (curcumin, epigallocatechin gallate)
Microtubule Stabilizers
- Davunetide (discontinued)
- Paclitaxel (BBB penetration issues)
Kinase Inhibitors
- GSK-3β inhibitors: Lithium, tideglusib
- CDK5 inhibitors: In development
- PP2A activators: Memantine, sodium selenate
- O-GlcNAcase inhibitors: Increase tau O-GlcNAcylation
- Reduces phosphorylation at same sites
- Total tau (t-tau): Marker of neuronal damage
- Phosphorylated tau (p-tau181, p-tau217, p-tau231): Specific to AD
- Tau PET ligands: Flortaucipir (AV-1451), MK-6240
- Correlates with clinical severity
- Predicts future cognitive decline
The study of Tau Pathology Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Tau pathology and neurodegeneration. Lancet Neurology. 2013;12(6):609-622.
-
Tau physiology and pathobiology in tau mitochondrial diseases. Trends in Cell Biology. 2019;29(5):370-383.
-
Classification and basic pathology of tauopathies. Acta Neuropathol. 2009;118(1):53-69.
-
The tauopathies: An overview. Lancet Neurology. 2020;19(11):953-964.
-
Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284(19):12845-12852.
-
Tau in physiology and pathology. Nat Rev Neurosci. 2012;13(1):51-62.
-
Association of missense and 5'-splice-site mutations in tau with FTDP-17. Nature. 1998;393(6686):702-705.
-
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
-
Role of abnormally phosphorylated tau in microtubule breakdown. Proc Natl Acad Sci. 1994;91(12):5562-5566.
-
Neocortical neurofibrillary tangles correlate with dementia severity. Arch Neurol. 1995;52(1):81-88.
-
Multiple isoforms of human microtubule-associated protein tau. Neuron. 1989;3(4):519-526.
-
Tau gene mutations in frontotemporal dementia and parkinsonism. Ann Neurol. 1998;44(3):416-423.
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
12 references |
| Replication |
0% |
| Effect Sizes |
50% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 45%